In short
This article discusses a clinical trial investigating the effectiveness of 2LVERU® JUNIOR and 2LVERU®, two medications containing Specific Nucleic Acid SNA-VERU, in treating non-genital warts. The study aims to compare these treatments with a placebo group to determine their efficacy in wart disappearance over a 6-month period. This randomized, placebo-controlled, double-blind study, known as the EVAsION Study, focuses on patients aged 3 years and older with common, plantar, or flat warts.
At a glance
- Study Type
- Randomized, placebo-controlled, double-blind clinical trial
- Medications Tested
- 2LVERU® JUNIOR and 2LVERU®
- Main Active Substance
- Specific Nucleic Acid SNA-VERU
- Condition Treated
- Non-genital warts (common, plantar, and flat warts)
- Primary Endpoint
- Wart disappearance at 6 months (end of treatment)
- Treatment Duration
- 6 months
- Eligible Age Group
- 3 years and older
- Key Exclusions
- Recent wart treatments, immunosuppressive therapy, pregnancy, breastfeeding
- Secondary Objectives
- Wart disappearance at 4 months, recurrence rates, pain evaluation, safety assessment
What is SPECIFIC NUCLEIC ACID SNA-VERU?
SPECIFIC NUCLEIC ACID SNA-VERU, also known as SNA-VERU or SPECIFIC NUCLEIC ACID - VERRUCA HUMAN PAPILLOMAVIRUS, is an active ingredient in medications designed to treat non-genital warts. It is part of a group of substances called nucleic acids, which are important components of our genetic material.
How Does It Work?
SNA-VERU works alongside other active ingredients such as interferon alfa, interleukin-1, interleukin-2, and ribonucleic acid. These substances are believed to help boost the body's immune response against the virus causing warts. By targeting the specific genetic material of the human papillomavirus (HPV) that causes warts, SNA-VERU may help the body fight off the infection more effectively.
What Medical Conditions Does It Treat?
The primary medical condition that SPECIFIC NUCLEIC ACID SNA-VERU is designed to treat is non-genital warts infection. This includes several types of warts:
- Common warts (Verruca vulgaris)
- Plantar warts (Verruca plantaris) - warts on the soles of the feet
- Flat warts (Verruca plana) - smoother, flatter warts that can appear on the face or other parts of the body
Current Clinical Trial
A clinical trial is currently underway to evaluate the effectiveness of medications containing SNA-VERU. This trial, known as the EVAsION Study, is comparing two products: 2LVERU® JUNIOR and 2LVERU®, against a placebo. The main goal is to see how well these treatments work in making warts disappear after 6 months of use.
How Is It Administered?
The medication containing SPECIFIC NUCLEIC ACID SNA-VERU comes in the form of granules in capsules that are meant to be opened. It is administered through oromucosal use, which means it's applied to the mucous membranes of the mouth. This method allows the medication to be absorbed into the bloodstream through the tissues in the mouth.
Dosage Information
The maximum daily dose of the medication is 380 mg, with a total maximum dose of 68.4 g over the course of treatment. The treatment period typically lasts for 6 months.
Effectiveness and Safety
The ongoing clinical trial aims to determine how effective SNA-VERU is in treating warts. The researchers are looking at several factors:
- How many warts disappear after 4 months and 6 months of treatment
- Whether the warts come back 3 months after the treatment ends
- How much pain patients experience during the study
- Any side effects or safety concerns that arise during treatment
Who Can Use This Treatment?
Based on the clinical trial information, this treatment may be suitable for:
- Patients aged 3 years and older
- People with common warts, plantar warts, or flat warts
However, the treatment may not be suitable for:
- Pregnant or breastfeeding women
- People with severe immune system disorders
- Patients undergoing chemotherapy or radiotherapy
- Those with known lactose intolerance
It's important to note that this information is based on an ongoing clinical trial. The full effectiveness and safety profile of SPECIFIC NUCLEIC ACID SNA-VERU will be better understood once the trial is completed and the results are analyzed.